Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in ...

Be hugged by an artificial 'muscle' in Japanese 'well-down' popup which involves relaxing into your natural self ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Emrelis is accelerating investor interest, validating biomarker-driven ADCs, and shaping distinct strategic ...

TCG Labs Soleil, which launched in 2024 in collaboration with The Column Group, is focused on building single-drug biotechs ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, highlights Emrelis’ potential to broaden its clinical impact ...

The Swiss company, which markets Elevidys abroad, said it believes the benefit-risk balance to treatment remains positive in ...

The Proteus Syndrome market is entering a pivotal decade, driven by increasing disease recognition, improving diagnostic techniques, development of genetic testing techniques and other innovative ...

DelveInsight’s Advanced Ovarian Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ ...

IHH Healthcare Berhad strengthens India presence through collaboration between Fortis Healthcare and Gleneagles Healthcare India for growth.

TOKYO -- Japanese pharmaceutical companies including Daiichi Sankyo and Fujifilm Holdings are increasing efforts to develop biopharmaceutical talent, aiming for 50% to 100% growth in such experts as ...